Surface Oncology, Inc.
(NASDAQ : SURF)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -0.63%61.200.0%$947.78m
GILDGilead Sciences, Inc. 0.22%76.231.0%$770.44m
AMGNAmgen, Inc. 1.52%259.001.3%$760.23m
REGNRegeneron Pharmaceuticals, Inc. 1.29%617.002.5%$687.28m
NVAXNovavax, Inc. -1.19%78.75102.0%$599.70m
BIIBBiogen, Inc. 0.52%266.151.6%$546.22m
VRTXVertex Pharmaceuticals, Inc. 1.28%289.931.9%$530.86m
ILMNIllumina, Inc. 1.21%373.003.5%$312.31m
ALXNAlexion Pharmaceuticals, Inc. 0.79%113.282.0%$230.93m
BMRNBioMarin Pharmaceutical, Inc. -0.04%125.794.3%$214.64m
SGENSeattle Genetics, Inc. 0.07%167.646.1%$202.00m
SRNESorrento Therapeutics, Inc. -4.04%6.651.8%$179.37m
SRPTSarepta Therapeutics, Inc. -0.34%165.1213.9%$168.09m
INCYIncyte Corp. 2.43%105.142.5%$163.88m
IMMUImmunomedics, Inc. 0.37%37.0511.0%$154.91m

Company Profile

Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company. It focuses on biological pathways critical to the immunosuppressive tumor microenvironment and the development of next-generation cancer therapies. The firm's pipeline includes two wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388); a clinical-stage collaboration with Novartis targeting CD73 (NZV930); and two preclinical programs, each focused primarily on activating natural killer or depleting regulatory T cells. The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA.